Overview

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Status:
Completed
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH).
Phase:
Phase 2
Details
Lead Sponsor:
Madrigal Pharmaceuticals, Inc.